Sirtex profits up eightfold
Friday, 28 August, 2009
Medical device company, Sirtex, best known for its anti-cancer SIR-Spheres, has announced an impressive boost in revenues of 72 per cent over the past financial year.
In an ASX announcement, the company has indicated a 42 per cent increase in sales of its flagship product, leading to a net profit before tax of $23 million, up from $2.5 million the previous financial year.
SIR-Spheres experienced growth in all markets, up 28 per cent in the US, 117 per cent in Europe and 17 per cent in Asia Pacific.
In today's trading, Sirtex (ASX:SRX) was up 7.7% to $4.64.
Anti-inflammatory agent could decrease septic shock mortality
Researchers have discovered a naturally occurring blood protein — a type of...
Less penicillin needed to treat Strep A infection than we thought
It's never been known exactly how much penicillin prevents sore throats — the most...
Stress disrupts emotion control in mental illness
Acute stress may impair key brain functions involved in managing emotions — particularly in...
